Curated News: Medical Meetings

• share
• favorite_border

Doctors at Mayo Clinic used a new catheter-based approach to draw out resistant pockets of infection that settle in the heart, known as right-sided infective endocarditis, without surgery. Unless treated quickly, the walled-off infections can grow, severely damaging heart valves and potentially affecting other organs as well. In a recent study, over 90% of the participants had their infection cleared, and they had lower in-hospital mortality compared to those whose infections remained.

• share
• favorite_border

The largest trial to examine the impact of colchicine in acute myocardial infarction (MI) found that both acute and long-term colchicine use did not reduce cardiovascular death, myocardial infarction, stroke, or ischemia-driven revascularization.

• share
• favorite_border

Results from the large-scale randomized ECLIPSE trial found that a lesion preparation strategy of routine orbital atherectomy had similar outcomes compared with conventional balloon angioplasty prior to implantation of a drug-eluting stent (DES) in severely calcified coronary arteries.

• share
• favorite_border

Kidney Week 2024: Live Event

• share
• favorite_border

Dr. Roy-Chaudhury will head up an organization—with nearly 21,000 health professionals representing 140 countries—dedicated to leading the fight against kidney diseases.

• share
• favorite_border

Allergist James Tracy, DO, of Omaha, NE, was installed as president of the American College of Allergy, Asthma and Immunology (ACAAI) at the ACAAI Annual Scientific Meeting on October 27 in Boston. Allergist Cherie Zachary, MD, of Eagan, MN, was elected ACAAI president-elect.

• share
• favorite_border

El alergista James Tracy, DO (Doctor en Medicina Osteopática), de Omaha, NE, fue instalado como presidente del Colegio Americano de Alergia, Asma e Inmunología (ACAAI) en la Reunión Científica Anual del ACAAI el 27 de octubre en Boston. La alergista Cherie Zachary, MD, de Eagan, Minnesota, fue elegida presidenta electa del ACAAI.

• share
• favorite_border

For kidney transplant recipients experiencing antibody-mediated rejection, the current standard of care involves removing donor-specific antibodies (DSAs) through plasmapheresis (PLEX)—a procedure that removes antibodies from the plasma portion of the blood. Results from a recent clinical trial reveal that an investigational drug called imlifidase, which cleaves and inactivates the type of antibodies that include DSAs, is more effective than PLEX. The research will be presented at ASN Kidney Week 2024 October 23–27.

• share
• favorite_border

IgA nephropathy is an autoimmune kidney disease, and complement, a component of the innate immune system, plays a role in the condition’s pathogenesis. Investigators have developed and tested a novel gene therapy that enters kidney cells and enables them to block complement activation. The research will be presented at ASN Kidney Week 2024 October 23– 27.

• share
• favorite_border

Chronic active antibody-mediated rejection (caAMR) is a common cause of allograft loss after transplantation, with no approved therapies. Clazakizumab, a monoclonal antibody that targets the inflammatory cytokine interleukin-6 (IL-6), stabilized kidney transplant recipients’ kidney function in a phase 2 trial. Investigators now have data from a phase 3 trial with clazakizumab. The findings from the Phase 3 IMAGINE trial, the largest placebo-controlled study in kidney transplant recipients with caAMR, will be presented at ASN Kidney Week 2024 October 23– 27.

• share
• favorite_border

The results of numerous high-impact phase 3 clinical trials that could affect kidney-related medical care will be presented in-person at ASN Kidney Week 2024 October 23–27.

• share
• favorite_border

Sodium-glucose co-transporter 2 (SGLT2) inhibitors reduce the risk of cardiovascular and kidney outcomes in patients with type 2 diabetes, but it is unclear whether their effects differ based on patients’ age. A recent analysis of clinical trial data reveals that the SGLT2 inhibitor canagliflozin benefited patients across all age categories. The findings will be presented at ASN Kidney Week 2024 October 23 – 27.

• share
• favorite_border

Prior efforts to identify novel kidney biomarkers as risk factors for chronic kidney disease (CKD) progression have typically evaluated proteins individually, which limits their prognostic power. The National Institute of Diabetes and Digestive and Kidney Diseases’ (NIDDK’s) CKD Biomarkers Consortium of investigators recently developed and tested novel dimensions of kidney health by combining a set of 17 urine and plasma biomarkers that had been individually associated with CKD progression. The research will be presented at ASN Kidney Week 2024 October 23– 27.

• share
• favorite_border

Glucagon-like peptide-1-receptor agonists (GLP-1RA) are medications that are increasingly prescribed for patients with type 2 diabetes and congestive heart failure. Reports of GLP-1RA–associated acute kidney injury (AKI) have emerged, but the risk of GLP-1RA–associated AKI among patients on anti-cancer drugs is unclear. Surprisingly, new research suggests that taking GLP-1RA is not associated with an increased risk of AKI in patients receiving anti-cancer therapies. The findings will be presented at ASN Kidney Week 2024 October 23– 27.

• share
• favorite_border

A recent analysis reveals that the number of chronic kidney disease (CKD) cases in women around the globe nearly tripled in the past three decades. Also, type 2 diabetes and hypertension were the leading causes of CKD-related deaths in women. The research will be presented at ASN Kidney Week 2024 October 23– 27.

• share
• favorite_border

IgA nephropathy (IgAN) is an autoimmune kidney disease driven by immune cells that express a protein called CD38 on their surface. A recent Phase 2 trial revealed that felzartamab, an investigational anti-CD38 monoclonal antibody, helps to reduce proteinuria and maintain patients’ kidney function. Investigators evaluated the molecular mechanisms underlying felzartamab’s potential efficacy in IgAN. The findings will be presented at ASN Kidney Week 2024 October 23– 27.

• share
• favorite_border

The results of numerous high-impact phase 3 clinical trials that could affect kidney-related medical care will be presented in-person at ASN Kidney Week 2024 October 23–27.

• share
• favorite_border

Cedars-Sinai experts in gastroenterology attending the Oct. 25-30 American College of Gastroenterology (ACG) Annual Scientific Meeting in Philadelphia are available for interviews about clinical and scientific developments in the field of digestive diseases.